Clinical Trials Logo
  1. Home
  2. Ductal Carcinoma In Situ
  3. NCT00669747

Study Of Intraductal Carboplatin In Women With Ductal Carcinoma In Situ (DCIS)

Ductal Carcinoma In Situ Clinical Trial

Official title:
A Phase II Randomized Study Of Intraductal Carboplatin In Women With Ductal Carcinoma In Situ

Clinical Trial Summary

The primary objective of this study is to compare the safety of 100 mg carboplatin administered intraductally once on Day 1 or twice on Days 1 and 15 in women with ductal carcinoma in situ (DCIS) undergoing surgical management 2 to 4 weeks following the Day 15 intraductal infusion. Secondary objectives are to characterize the biologic and clinical effects with respect to: pharmacokinetics, extent of disease on MRI and mammogram, histopathological assessment of DCIS, and biomarker measurement of Ki-67, TUNEL and G-actin.

Clinical Trial Description

This is a randomized, 3-arm, saline-controlled study involving women undergoing surgical management of DCIS. Forty-five (45) women who have been diagnosed with DCIS by core biopsy will receive intraductal administration of either carboplatin or normal saline (NS) into the DCIS-involved breast duct. Thirty (30) patients (i.e., 15 patients per arm) will receive two intraductal infusions of either 100 mg of carboplatin or NS on Days 1 and 15. Fifteen (15) patients will receive an intraductal infusion of 100 mg carboplatin on Day 1 and an intraductal infusion of NS on Day 15. Patients will undergo surgical resection 2 to 4 weeks following the Day 15 intraductal infusion (i.e. 4 to 6 weeks from diagnosis).

The effect of carboplatin on DCIS in the pre-treatment core biopsy specimen and the resection specimen will be assessed. Venous blood samples will be collected for carboplatin PK analysis pre-dose and at 30 minutes, 1, 2, 4, and 8 hours following intraductal infusions on Days 1 and 15. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00669747
Study type Interventional
Source Windy Hill Medical, Inc.
Contact Jane Doerr, RN, MSN
Phone 949-636-4737
Email jdoerr@whmed.com
Status Recruiting
Phase Phase 2
Start date May 2008
Completion date December 2009
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02889458 - Hong Kong Breast Cancer Study
Completed NCT00757302 - Intraoperative Gamma Camera for Breast Cancer Surgery Phase 3
Recruiting NCT03216421 - Intraoperative Radiation Therapy (IORT) in DCIS N/A
Completed NCT03775213 - Acceptability of Active Monitoring (AM) as a Treatment Option for Ductal Carcinoma in Situ (DCIS) N/A
Active, not recruiting NCT00605982 - Breast MRI as a Preoperative Tool for DCIS N/A
Enrolling by invitation NCT04365114 - Patient Outcomes From Second Film-readers and Test Threshold Relaxation in Breast Screening
Completed NCT04248179 - The Ultrasound-guided Multiple-injection Costotransverse Block for Mastectomy and Primary Reconstructive Surgery. Phase 4
Withdrawn NCT05032079 - Subzero and Scorpion Trial N/A
Recruiting NCT05218044 - Cryoablation as a Minimally Invasive Alternative to Surgery for Managing Ductal Carcinoma In Situ N/A
Active, not recruiting NCT01644669 - Safety and Efficacy Study of the Xoft® Axxent® eBx® IORT System® N/A
Recruiting NCT06133647 - Demographics, Characteristics and Outcomes of Male Breast Cancer Patients at Methodist Health System
Completed NCT01815476 - The Prone Breast Radiation Therapy Trial N/A
Not yet recruiting NCT06033092 - Low Dose TamOxifen and LifestylE Changes for bReast cANcer prevenTion Phase 2
Terminated NCT02137252 - Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer Phase 2
Terminated NCT01060345 - A Pilot Study of Chemo-prevention of Green Tea in Women With Ductal Carcinoma in Situ Phase 2
Completed NCT00742222 - Electronic Xoft Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For Treatment of Early Stage Breast Cancer Phase 4
Active, not recruiting NCT02909426 - The Mammography and Ultrasonography STudy for Breast Cancer Screening Effectiveness
Recruiting NCT02928978 - Ruxolitinib for Premalignant Breast Disease Phase 2
Completed NCT03375892 - The Use of Deep Inspiration Breath Hold and Prone Irradiation to Decrease Cardiac Radiation Exposure N/A
Withdrawn NCT03437915 - BrUOG 351: PRE-OPERATIVE APBI USING NIBB N/A